CompletedPhase 4ACTRN12607000565448

A study to compare the preference of two contrasting paracetamol formulations in the management of osteoarthritis pain

Sponsor

GlaxoSmithKline Consumer Healthcare

Enrollment

260 participants

Start Date

Nov 1, 2007

Study Type

Interventional

Conditions

Osteoarthritis of the knee

Summary

Paracetamol is first-line pain management for osteoarthrits and this study is designed to investigate patient preference for sustained release paracetamol given 3xdaily compared with standard paracetamol tablet given 4xdaily.

Eligibility

Sex: Both males and femalesMin Age: 45 Yearss

Plain Language Summary

Simplified for easier understanding

This study is about a study to compare the preference of two contrasting paracetamol formulations in the management of osteoarthritis pain. It is looking for adults aged 45 and older to participate. To join, participants should meet requirements such as: At least 45 years of age, good general health, diagnosis of osteoarthritis of the knee with the pain worse in one knee, pain must be suitable for treatment with a simple analgesic. Participants will be guided through the study procedures by the research team and may need to attend scheduled visits.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

All patients will receive both treatments. Two weeks treatment with immediate release paracetamol (1000mg four times daily - oral), and two weeks of extended release paracetamol (1330mg three times da